Figure 10.

The impact of IVIg (GamaSTAN) and HLA-I polyreactive mAb (TFL-007) on the primary alloantibody DRB1*0101 (IgG), secreted by activated B-lymphocytes obtained from an alloimmunized woman. GamaSTAN S/D IVIg was used at 1:100 dilution, 1.5 mg. protein/mL. At the time when the IVIg was added, the cytokine combo and anti-CD40 antibody were not added. In all panels, the mean fluorescent intensity (MFI) of alloantibody secretion is compared between the medium control and treatment with IVIg and HLA-I polyreactive IgG2a mAb TFL-007. IVIg inhibited the secretion of the primary alloantibody at a significant level (p² = 0.01). HLA-I polyreactive mAb inhibited the secretion of the primary alloantibody at a higher significant level (p² = 0.0005). This is an original figure.